Today's Insider Trading Highlights — June 02, 2026
📅 Published: June 02, 2026 at 12:10 PM UTC
3 Cluster Buys5 Insider Purchases
On June 02, 2026, we detected 3 new cluster buys including a $30M purchase in $QTTB by 2 insiders, and 5 notable insider purchases. Malka Meyer (Director) bought $20M of $HOOD. Data sourced from SEC Form 4 filings analyzed by Average Insider.
⚠️ For information purposes only. This information is provided for informational purposes only and does not constitute investment advice, financial advice, trading advice, or any other type of advice. All investments carry risk, including the potential loss of principal. Past performance is not indicative of future results. You should consult with a qualified financial advisor, accountant, or other professional before making any investment decisions. The information contained in this newsletter is not intended to be a substitute for professional financial advice.
📊 Insider Trading Insights — June 02, 2026
Tracking insider purchases and cluster buys over the past 7 days. Insider buying can indicate confidence in a company's future, while cluster buys (multiple insiders buying around the same time) are particularly noteworthy signals.
🔥 Cluster Buys
$11.66
Current Price
52W: $1.34 – $13.15
$3.21
Fair Value
Participants 2 insiders | Total Shares 3,750,000 | Total Value $30,000,000 |
Timeframe 0 days | Date Range May 28, 2026 – May 28, 2026 |
👥 Participant Details
P&L: +45.8% (+$2,287,500) |
P&L: +45.8% (+$4,575,000) | ||||
P&L: +45.8% (+$4,575,000) |
P&L: +45.8% (+$2,287,500) |
📊 Valuation & Analyst Info
Fair Value: $3.21 (-72.5% overvalued vs current price)
P/E Ratio: 1.4 (0.9x below Biotechnology avg (23.2)) (0.9x below Healthcare avg (25.4))
Analyst Consensus: Hold
Price Target: $13.50 (Low: $13.00 | High: $14.00 | Median: $13.50)
$0.84
Current Price
52W: $0.16 – $3.39
$1.46
Fair Value
Participants 2 insiders | Total Shares 8,661,883 | Total Value $5,050,005 |
Timeframe 1 days | Date Range May 27, 2026 – May 28, 2026 |
👥 Participant Details
P&L: +106.0% (+$52,987) |
P&L: +44.0% (+$2,198,975) |
📊 Valuation & Analyst Info
Fair Value: $1.46 (+73.2% undervalued vs current price)
P/E Ratio: -0.6
Analyst Consensus: Buy
Price Target: $1.00 (Low: $1.00 | High: $1.00 | Median: $1.00)
📰 Recent News (Last 7 Days)
$13.09
Current Price
52W: $10.52 – $14.50
$-1.83
Fair Value
Participants 2 insiders | Total Shares 70,752 | Total Value $926,650 |
Timeframe 5 days | Date Range May 27, 2026 – Jun 01, 2026 |
👥 Participant Details
P&L: +2.9% (+$3,700) |
P&L: +2.1% (+$2,700) | ||||
P&L: -2.1% ($9,711) |
P&L: +1.2% (+$1,598) | ||||
P&L: +1.6% (+$1,207) |
📊 Valuation & Analyst Info
Fair Value: $-1.83 (-113.9% overvalued vs current price)
P/E Ratio: -31.3
Analyst Consensus: Buy
Price Target: $17.00 (Low: $17.00 | High: $17.00 | Median: $17.00)
📰 Recent News (Last 7 Days)
💰 Individual Insider Buys
$90.73
Current Price
52W: $63.52 – $153.86
$-49.82
Fair Value
Transaction Date May 28, 2026 | Shares 249,000 | Purchase Price $80.39 |
Purchase Value $20,018,206 |
P&L: +12.9% (+$2,573,564)
📊 Valuation & Analyst Info
Fair Value: $-49.82 (-154.9% overvalued vs current price)
P/E Ratio: 53.4 (0.3x above Financial - Capital Markets avg (42.5)) (1.0x above Financial Services avg (26.2))
Analyst Consensus: Buy
Price Target: $109.62 (Low: $82.00 | High: $145.00 | Median: $110.00)
📰 Recent News (Last 7 Days)
📈 Recent Earnings: 2026-07-29
$11.66
Current Price
52W: $1.34 – $13.15
$3.21
Fair Value
Transaction Date May 28, 2026 | Shares 1,250,000 | Purchase Price $8.00 |
Purchase Value $10,000,000 |
P&L: +45.8% (+$4,575,000)
📊 Valuation & Analyst Info
Fair Value: $3.21 (-72.5% overvalued vs current price)
P/E Ratio: 1.4 (0.9x below Biotechnology avg (23.2)) (0.9x below Healthcare avg (25.4))
Analyst Consensus: Hold
Price Target: $13.50 (Low: $13.00 | High: $14.00 | Median: $13.50)
📰 Recent News (Last 7 Days)
📈 Recent Earnings: 2026-08-05
$11.66
Current Price
52W: $1.34 – $13.15
$3.21
Fair Value
Transaction Date May 28, 2026 | Shares 1,250,000 | Purchase Price $8.00 |
Purchase Value $10,000,000 |
P&L: +45.8% (+$4,575,000)
📊 Valuation & Analyst Info
Fair Value: $3.21 (-72.5% overvalued vs current price)
P/E Ratio: 1.4 (0.9x below Biotechnology avg (23.2)) (0.9x below Healthcare avg (25.4))
Analyst Consensus: Hold
Price Target: $13.50 (Low: $13.00 | High: $14.00 | Median: $13.50)
📰 Recent News (Last 7 Days)
📈 Recent Earnings: 2026-08-05
$11.66
Current Price
52W: $1.34 – $13.15
$3.21
Fair Value
Transaction Date May 28, 2026 | Shares 625,000 | Purchase Price $8.00 |
Purchase Value $5,000,000 |
P&L: +45.8% (+$2,287,500)
📊 Valuation & Analyst Info
Fair Value: $3.21 (-72.5% overvalued vs current price)
P/E Ratio: 1.4 (0.9x below Biotechnology avg (23.2)) (0.9x below Healthcare avg (25.4))
Analyst Consensus: Hold
Price Target: $13.50 (Low: $13.00 | High: $14.00 | Median: $13.50)
📰 Recent News (Last 7 Days)
📈 Recent Earnings: 2026-08-05
$11.66
Current Price
52W: $1.34 – $13.15
$3.21
Fair Value
Transaction Date May 28, 2026 | Shares 625,000 | Purchase Price $8.00 |
Purchase Value $5,000,000 |
P&L: +45.8% (+$2,287,500)
📊 Valuation & Analyst Info
Fair Value: $3.21 (-72.5% overvalued vs current price)
P/E Ratio: 1.4 (0.9x below Biotechnology avg (23.2)) (0.9x below Healthcare avg (25.4))
Analyst Consensus: Hold
Price Target: $13.50 (Low: $13.00 | High: $14.00 | Median: $13.50)
📰 Recent News (Last 7 Days)
📈 Recent Earnings: 2026-08-05
⚠️ Important Disclaimers
Investment Disclaimer: This content is for informational purposes only and should not be considered investment advice.
Data Accuracy: All information is sourced from SEC filings and third-party data providers. Errors or omissions may occur.
Market Risks: Past insider buying activity does not guarantee future performance.
Professional Advice: Consult with qualified financial professionals before making any investment decisions.
📚 Deep Dive Resources
Data sourced from SEC filings. This is for informational purposes only.
Want to receive these newsletters in your inbox? Sign up here